

Yong-xian Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2185916/publications.pdf>

Version: 2024-02-01

114
papers

2,132
citations

279798

23
h-index

302126

39
g-index

121
all docs

121
docs citations

121
times ranked

2750
citing authors

#	ARTICLE	IF	CITATIONS
1	Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy. Bone Marrow Transplantation, 2022, , .	2.4	2
2	Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer Journal, 2022, 12, 20.	6.2	14
3	Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion. Bone Marrow Transplantation, 2022, 57, 326-328.	2.4	1
4	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis Pathways. Advanced Science, 2022, 9, e2103508.	11.2	21
5	Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study. Supportive Care in Cancer, 2022, 30, 3321-3327.	2.2	3
6	Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Current Oncology, 2022, 29, 490-496.	2.2	6
7	Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 2022, 139, 3376-3386.	1.4	36
8	HLA-matched allogeneic anti-CD19 CAR-T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. Immunomedicine, 2022, 2, .	0.7	0
9	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies. Cancer Letters, 2022, 538, 215691.	7.2	4
10	The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies. Biomarker Research, 2022, 10, 28.	6.8	9
11	é¶âCD19âµCEâæŠ—âŽŸâ—â½“Tç»†èfžæ²»ç—æYæESBæ·â´ç»†èfžç™½èjç—...â¼´é«“â—ââæ,èè€...çšš,,â%â.3.”æCSâ¹CEææ%ææ		
12	CAR-Tç»†èfžæ²»èjçæ²³ç»Ÿæ¶æSè,çæ²»ç—çšš,ç”ç©¶èjâ±•. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University		
13	CAR-T cells for cancer immunotherapyâ€”the barriers ahead and the pathsÂthrough. International Reviews of Immunology, 2022, 41, 567-581.	3.3	1
14	Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. Bone Marrow Transplantation, 2022, 57, 1350-1353.	2.4	2
15	Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement. Regenerative Therapy, 2022, 21, 34-36.	3.0	2
16	Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).. Journal of Clinical Oncology, 2022, 40, 8004-8004.	1.6	11
17	Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as second-line therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.. Journal of Clinical Oncology, 2022, 40, e19509-e19509.	1.6	0
18	Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 293-296.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis. Bone Marrow Transplantation, 2021, 56, 664-672.	2.4	12
20	Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2021, 56, 570-580.	2.4	25
21	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies. Cell Transplantation, 2021, 30, 096368972110255.	2.5	16
22	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. Journal of Cancer, 2021, 12, 5423-5431.	2.5	5
23	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Stem Cell Investigation, 2021, 8, 1-1.	3.0	17
24	CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2021, 27, 2764-2772.	7.0	122
25	Understanding of cytokines and targeted therapy in macrophage activation syndrome. Seminars in Arthritis and Rheumatism, 2021, 51, 198-210.	3.4	14
26	CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. Bone Marrow Transplantation, 2021, 56, 1642-1650.	2.4	14
27	Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia. Molecular Therapy, 2021, 29, 645-657.	8.2	39
28	Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. Frontiers in Immunology, 2021, 12, 627764.	4.8	28
29	Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer, 2021, 21, 606.	2.6	52
30	Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. Current Medical Science, 2021, 41, 420-430.	1.8	5
31	New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2021, 11, 702644.	2.8	24
32	The CD226-ERK1/2-LAMP1 pathway is an important mechanism for V β 9V α 2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells. Cancer Science, 2021, 112, 3233-3242.	3.9	2
33	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research, 2021, 9, 1061-1070.	3.4	37
34	Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 2021, 12, 702152.	3.5	2
35	Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. Journal of Hematology and Oncology, 2021, 14, 113.	17.0	32
36	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. Frontiers in Oncology, 2021, 11, 713577.	2.8	27

#	ARTICLE	IF	CITATIONS
37	Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study. American Journal of Hematology, 2021, 96, 1429-1440.	4.1	1
38	Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. Clinical Cancer Research, 2021, 27, 6384-6392.	7.0	27
39	BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement. Journal of Immunotherapy, 2021, Publish Ahead of Print, 25-34.	2.4	8
40	Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement. Bone Marrow Transplantation, 2021, 56, 3088-3090.	2.4	5
41	The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). BMC Medical Imaging, 2021, 21, 145.	2.7	4
42	Integrated Single-Cell Bioinformatics Analysis Reveals Intrinsic and Extrinsic Biological Characteristics of Hematopoietic Stem Cell Aging. Frontiers in Genetics, 2021, 12, 745786.	2.3	2
43	Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse. Frontiers in Oncology, 2021, 11, 750218.	2.8	12
44	Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission. Frontiers in Oncology, 2021, 11, 755584.	2.8	6
45	Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy. Blood, 2021, 138, 2842-2842.	1.4	0
46	Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. Journal of Cellular Physiology, 2020, 235, 2080-2090.	4.1	9
47	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. Journal of Zhejiang University: Science B, 2020, 21, 29-41.	2.8	17
48	Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1476-1478.	2.4	8
49	A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Cancer Journal, 2020, 10, 105.	6.2	20
50	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. Frontiers of Medicine, 2020, 14, 711-725.	3.4	8
51	Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. Journal of Hematology and Oncology, 2020, 13, 153.	17.0	172
52	Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 1534.	4.8	15
53	Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma. Medicine (United States), 2020, 99, e22510.	1.0	9
54	Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy. Regenerative Therapy, 2020, 15, 281-284.	3.0	4

#	ARTICLE	IF	CITATIONS
55	Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma. <i>JAMA Dermatology</i> , 2020, 156, 1026.	4.1	8
56	Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 42.	17.0	56
57	Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy. <i>Regenerative Therapy</i> , 2020, 14, 271-274.	3.0	3
58	CAR-T cells: the Chinese experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1293-1308.	3.1	4
59	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.8	30
60	Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 956-964.	2.0	10
61	CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. <i>Bone Marrow Transplantation</i> , 2020, 55, 717-721.	2.4	6
62	Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib. <i>Regenerative Therapy</i> , 2020, 14, 40-42.	3.0	3
63	Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. <i>Cell Transplantation</i> , 2020, 29, 096368972091943.	2.5	16
64	The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 52-52.	1.4	8
65	CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study. <i>Blood</i> , 2020, 136, 34-34.	1.4	11
66	COVID-19 in Hematologic Malignancies: Big Challenges. <i>Clinical Hematology International</i> , 2020, 2, 173.	1.7	4
67	Weathering the storm: COVID-19 infection in patients with hematological malignancies. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 921-939.	2.8	2
68	Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy. <i>Blood</i> , 2020, 136, 35-36.	1.4	1
69	Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 2072-2080.	2.4	18
70	Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT. <i>Regenerative Therapy</i> , 2019, 11, 139-142.	3.0	5
71	Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. <i>BMC Cancer</i> , 2019, 19, 242.	2.6	6
72	Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1092-1098.	2.0	79

#	ARTICLE	IF	CITATIONS
73	Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2019, 54, 969-972.	2.4	13
74	A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. Bone Marrow Transplantation, 2019, 54, 1208-1217.	2.4	37
75	Withdrawal: Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. Journal of Cellular Physiology, 2019, 234, 16654-16654.	4.1	3
76	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies. Blood, 2019, 134, 3220-3220.	1.4	1
77	Potent Anti-Tumor Activity of Bcma CART-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry. Blood, 2019, 134, 1859-1859.	1.4	14
78	The effectiveness of interferon- γ combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation. Leukemia and Lymphoma, 2018, 59, 3018-3019.	1.3	0
79	CXCR4 Antagonist AMD3100 Promotes Mesenchymal Stem Cell Mobilization in Rats Preconditioned with the Hypoxia-Mimicking Agent Cobalt Chloride. Stem Cells and Development, 2018, 27, 466-478.	2.1	16
80	CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Annals of Hematology, 2018, 97, 781-789.	1.8	24
81	Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma. Bone Marrow Transplantation, 2018, 53, 1340-1344.	2.4	8
82	Current development of chimeric antigen receptor T-cell therapy. Stem Cell Investigation, 2018, 5, 44-44.	3.0	26
83	Profile of Capillary-Leak Syndrome in Patients Received Chimeric Antigen Receptor T Cell Therapy. Blood, 2018, 132, 5204-5204.	1.4	7
84	Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Research and Treatment, 2018, 50, 1462-1466.	3.0	11
85	Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance. Blood, 2018, 132, 1423-1423.	1.4	1
86	Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematological Oncology, 2017, 35, 821-827.	1.7	37
87	Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 2017, 35, 118-124.	1.7	9
88	Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. Oncoimmunology, 2017, 6, e1277307.	4.6	24
89	Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/ β -catenin signaling pathway. BMC Cancer, 2017, 17, 161.	2.6	38
90	ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma. Gene, 2017, 627, 255-262.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. <i>Experimental Hematology and Oncology</i> , 2017, 6, 10.	5.0	64
92	SNX2â€“ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 2261-2263.	1.3	4
93	Potent Anti-leukemia Activities of Chimeric Antigen Receptorâ€“Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 3297-3306.	7.0	106
94	Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1347-1356.	3.3	40
95	mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. <i>Stem Cell Research and Therapy</i> , 2017, 8, 292.	5.5	35
96	Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7028-7028.	1.6	12
97	Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14549-e14549.	1.6	3
98	Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 70.	17.0	151
99	Cunninghamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2016, 181, 753-758.	3.1	6
100	A promising sword of tomorrow: Human β T cell strategies reconcile allo-HSCT complications. <i>Blood Reviews</i> , 2016, 30, 179-188.	5.7	19
101	Regular Prophylactic Donor Lymphocyte Infusion Is Effective and Safe to Prevent Relapse after Hematopoietic Cell Transplantation in High-Risk Patients. <i>Blood</i> , 2016, 128, 3439-3439.	1.4	0
102	Expansion of CD56-Bright NK Cell in Patients with Steroid-Refractory Graft-Versus-Host Disease Treated with Basiliximab and Etanercept. <i>Blood</i> , 2016, 128, 5793-5793.	1.4	0
103	Phenotypical and Functional Characterization of Bone Marrow Mesenchymal Stem Cells in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1020-1028.	2.0	12
104	Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/ β -catenin signaling pathway. <i>Journal of Hematology and Oncology</i> , 2015, 8, 1.	17.0	122
105	First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3778-3778.	1.4	43
106	$\langle \text{mml:math xmlns:mml}=\text{"http://www.w3.org/1998/Math/MathML"} \text{id}=\text{"M1"} \rangle \langle \text{mml:mi} \rangle \beta^3 \langle \text{mml:mi} \rangle \langle \text{mml:mi} \rangle \beta^1 \langle \text{mml:mi} \rangle \langle \text{mml:math} \rangle$ T Cell and Other Immune Cells Crosstalk in Cellular Immunity. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	18
107	Rapamycin together with TGF- β 1, IL-2 and IL-15 induces the generation of functional regulatory β T cells from human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2014, 402, 82-87.	1.4	13
108	Foxp3+ Regulatory T Cell Subsets Are Induced In Alloreactive Microenvironment and Associated With Chronic Graft-Versus-Host Disease Severity After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3307-3307.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice. <i>Annals of Hematology</i> , 2012, 91, 1803-1812.	1.8	1
110	Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1099-1111.	2.0	8
111	Allogeneic Hematopoietic Stem Cell Transplantation From HBsAg-Positive Donors Into HBsAg-Negative Recipients: A Safety and Practicable Regimen Under Active Prophylactic Anti-HBV Therapy. <i>Blood</i> , 2011, 118, 1949-1949.	1.4	0
112	Ex Vivo-Expanded $\text{V}\alpha^3\text{9V}\alpha^2$ T Cells Can Efficiently Kill Human Acute Myeloid Leukemia Cells Via Trogocytosis. <i>Blood</i> , 2011, 118, 580-580.	1.4	0
113	Donor-Derived Solid Malignancies after Hematopoietic Stem Cell Transplantation. <i>Onkologie</i> , 2010, 33, 195-200.	0.8	5
114	Bronchiolitis Obliterans Following Unrelated-Donor Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 4504-4504.	1.4	0